TORONTO, CANADA -- (June 16, 2020) Oncoustics, today announced that it is participating in Digital Medicine & Medtech Showcase 2021, part of Biotech Showcase™ 2021, and providing an on-demand company presentation. This year registered attendees to Digital Medicine & Medtech Showcase are able to access recorded company presentations beginning November 30th and continuing through and beyond the event. 24x7 on-demand access allows attendees to view presentations at their convenience, avoiding conflicts with busy meeting schedules during the main event week.

Beth Rogozinski, CEO of Oncoustics, will be presenting and taking live meetings all week during Digital Medicine & Medtech Showcase.  In addition to the company presentation, Beth will be participating in a live panel discussion on The Digital Health Revolution during the education tracks of the Biotech Showcase at 2:30PT Monday, January 11th:

“The Digital Medicine and Medtech Showcase is an exceptional event for leaders in digital medicine and health innovation and is a perfect event for Oncoustics as we’re expanding our partnerships and raising our next round,”  said Beth Rogozinski, CEO of Oncoustics.  “This year’s virtual event is boasting exceptional delegates and participants and I’m excited to introduce this audience to the innovations we’ve developed and are delivering with our novel AI driven approach.”

Oncoustics, a Stanford University spinout, is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, they are not doing image recognition. Instead, they apply AI to raw ultrasound signals from readily available handheld ultrasound devices to rapidly differentiate healthy versus diseased tissues. Oncoustics has its first FDA filings underway for its OnX™ product that detects liver fibrosis. Several follow-on liver products are in development.  The company  also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.

Digital Medicine & Medtech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on providing the very latest in digital medicine, medtech innovations, and cutting edge technologies. It helps drive advances by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference is part of the Biotech Showcase family of events, and takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that Oncoustics will be presenting at Digital Medicine & Medtech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Digital Medicine & Medtech Showcase a prime occasion for digital medicine and medtech entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery and healthcare.”

Digital Medicine & Medtech Showcase, part of the Biotech Showcase family of events, is an investor and networking conference devoted to providing private and public digital medicine and medtech companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 5th year, Digital Medicine & Medtech Showcase is a well-established, highly respected conference featuring multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Digital Medicine & Medtech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

Oncoustics (www.oncoustics.com) is a world leader in AI-based ultrasound data extraction enabling real-time imaging and non-invasive diagnosis in the medical market starting with liver disease. Oncoustics’ platform operates in a hardware agnostic fashion, and enables a whole new level of access to care with the benefits of ease of use, affordability, and optimizing current clinical workflow. Using the Oncoustics’ platform, physicians will be able to visualize areas of interest in the liver or prostate, and specifically retrieve analysis from those areas. The Oncoustics’ solution for ultrasound, including liver and prostate applications, will be submitted for regulatory approval in the United States (FDA 510(k)), Canada (Health Canada medical device license) and the European Union (CE Mark).

Contacts:
Meaghan Gray
mgray@oncoustics.com
Oncoustics
www.oncoustics.com

‍Follow Oncoustics on Twitter at @Oncoustics and Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.